1. Home
  2. GBR vs ARTL Comparison

GBR vs ARTL Comparison

Compare GBR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Concept Energy Inc

GBR

New Concept Energy Inc

HOLD

Current Price

$0.75

Market Cap

3.7M

Sector

Energy

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$5.41

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBR
ARTL
Founded
1978
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
GBR
ARTL
Price
$0.75
$5.41
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
89.6K
5.9M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$155,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.16
N/A
52 Week Low
$0.67
$0.88
52 Week High
$1.78
$28.60

Technical Indicators

Market Signals
Indicator
GBR
ARTL
Relative Strength Index (RSI) 41.19 48.94
Support Level N/A $2.24
Resistance Level $0.87 $5.56
Average True Range (ATR) 0.08 2.14
MACD -0.02 -0.40
Stochastic Oscillator 11.96 14.42

Price Performance

Historical Comparison
GBR
ARTL

About GBR New Concept Energy Inc

New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: